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STUDY PROTOCOL Open Access
A multicentre, randomised controlled trial
to compare the clinical and cost-
effectiveness of Lee Silverman Voice
Treatment versus standard NHS Speech
and Language Therapy versus control in
Parkinson’s disease: a study protocol for a
randomised controlled trial
C. M. Sackley1,2†, C. Rick3,4*† , P. Au4, M. C. Brady5, G. Beaton6, C. Burton7, M. Caulfield8, S. Dickson5, F. Dowling9,
M. Hughes4, N. Ives4, S. Jowett10, P. Masterson-Algar8, A. Nicoll5, S. Patel4, C. H. Smith11, R. Woolley4,
C. E. Clarke12,13 and on behalf of the PD COMM Collaborative Group
Abstract
Background: Parkinson’s disease (PD) affects approximately 145,519 people in the UK. Speech impairments are common
with a reported prevalence of 68%, which increase physical and mental demands during conversation, reliance on family
and/or carers, and the likelihood of social withdrawal reducing quality of life. In the UK, two approaches to Speech and
Language Therapy (SLT) intervention are commonly available: National Health Service (NHS) SLT or Lee Silverman Voice
Treatment (LSVT LOUD®). NHS SLT is tailored to the individuals’ needs per local practice typically consisting of six to eight
weekly sessions; LSVT LOUD® comprises 16 sessions of individual treatment with home-based practice over 4 weeks. The
evidence-base for their effectiveness is inconclusive.
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Methods/design: PD COMM is a phase III, multicentre, three-arm, unblinded, randomised controlled trial. Five hundred and
forty-six people with idiopathic PD, reporting speech or voice problems will be enrolled. We will exclude those with a
diagnosis of dementia, laryngeal pathology or those who have received SLT for speech problems in the previous 2 years.
Following informed consent and completion of baseline assessments, participants will be randomised in a 1:1:1 ratio to no-
intervention control, NHS SLT or LSVT LOUD® via a central computer-generated programme, using a minimisation procedure
with a random element, to ensure allocation concealment. Participants randomised to the intervention groups will start
treatment within 4 (NHS SLT) or 7 (LSVT LOUD®) weeks of randomisation.
Primary outcome: Voice Handicap Index (VHI) total score at 3 months. Secondary outcomes include: VHI subscales,
Parkinson’s Disease Questionnaire-39; Questionnaire on Acquired Speech Disorders; EuroQol-5D-5 L; ICECAP-O;
resource utilisation; adverse events and carer quality of life. Mixed-methods process and health economic
evaluations will take place alongside the trial. Assessments will be completed before randomisation and at 3, 6
and 12 months after randomisation.
The trial started in December 2015 and will run for 77 months. Recruitment will take place in approximately 42
sites around the UK.
Discussion: The trial will test the hypothesis that SLT is effective for the treatment of speech or voice problems
in people with PD compared to no SLT. It will further test whether NHS SLT or LSVT LOUD® provide greater
benefit and determine the cost-effectiveness of both interventions.
Trial registration: International Standard Randomised Controlled Trials Number (ISRCTN) Registry, ID: 12421382.
Registered on 18 April 2016.
Keywords: Idiopathic Parkinson’s disease, Lee Silverman voice treatment, Speech and language therapy, Randomised
controlled trial, Dysarthria
Background
In prevalence and years lived with disability, Parkinson’s
disease (PD) is the fastest-growing neurological disorder
in the world [1], and it affects approximately 145,519
people in the UK. PD is a complex, progressive condition
with a range of motor and non-motor symptoms [2].
Speech impairments are common in the PD population
with a reported prevalence of 68% for patient-perceived
problems and 71% for listener-rated speech impairment
[3]. In a study of 125 participants with PD [4], 38% placed
speech among their top four concerns and, in another
study, 29% of participants [5] reported speech problems to
be among their greatest present difficulties. Miller et al.
[6] noted how changes in communication led to increased
physical and mental demands during conversation, an in-
creased reliance on family members and/or carers, and an
increased likelihood of social withdrawal. The speech of
people with PD is often perceived as sounding quiet and
imprecise, creating a potential social barrier to communi-
cation [7]. A qualitative study involving 24 people living
with PD identified problems with speaking as an activity.
The interviewees reported having to think more about
speaking; weighing up the value versus the effort of speak-
ing; having negative feelings about speaking; finding that
speaking is influenced by different people and places; and
having to adjust to the effect of speaking of the disease
progression and their medication [8]. Overall, impair-
ments of speech have been recognised to reduce the qual-
ity of life of people with PD [7, 9, 10].
Speech and Language Therapy (SLT) for speech diffi-
culties in people with PD in the UK aims to improve
communication. Some therapy approaches engage the
person with PD in exercises to improve motor skills,
others support the communication partnership between
the person with PD and their communication partner,
while others consider augmentation, or alternative
means of communication. Following assessment and dis-
cussion with the person with PD, an individually tailored
therapy plan is developed to address their needs and
those of their family. For the purposes of the PD COMM
trial, any of the above will be included in the interven-
tion arm called ‘standard National Health Service (NHS)
SLT’. This ‘standard NHS SLT’ is distinct from the other
trial intervention arm which comprises Lee Silverman
Voice Treatment (LSVT LOUD®) [11]. Within the PD
COMM trial two types of SLT will be assessed: standard
NHS SLT and LSVT LOUD® [11] against a no-SLT
control.
Standard NHS SLT can include any of the above with
the therapist selecting from multifaceted therapy compo-
nents and tailoring these to the needs of the individual,
their impairment and participation targets and within
the constraints for that particular clinical service [6].
Typically, weekly sessions over 6–8 weeks are prescribed,
either individually or in groups [12, 13]. LSVT LOUD®
differs from standard NHS SLT in that it is a more pre-
scriptive therapy. The focus of LSVT® is to ‘think loud’;
improving phonation and vocal loudness through better
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vocal fold adduction [14] over an intervention lasting for
16 sessions. The single focus and intensive delivery is
used to ‘recalibrate’ the patient, so that they recognise
that a voice which sounds too loud to them is necessary
for them to be understood by other people. LSVT
LOUD® is increasingly being used in the NHS, but in the
context of PD COMM, standard NHS SLT excludes the
delivery of LSVT®.
A Cochrane review of SLT versus no intervention (last
search date 11 April 2011) identified three randomised
controlled trials (RCTs) of differing SLT interventions
versus no intervention (n = 63) [15]. The SLT evaluated
varied from: 10 h over 4 weeks of individual therapy fo-
cussing on prosodic features of pitch and volume rein-
forced by visual feedback [16]; 16 h over 4 weeks of
LSVT [11]; and 35–40 h over 2 weeks improving loud-
ness and pitch variation, respiration, voice production
and intelligibility reinforced by visual feedback primarily
in a group setting [17]. The review authors concluded
that while outcome measures improved following SLT,
the small participant numbers, low RCT quality and the
possibility of publication bias, meant that the efficacy of
SLT for progressive dysarthria in PD against a placebo
or no intervention could not be confirmed or refuted. In
another Cochrane review of six trials comparing differ-
ent theoretical approaches to SLT provision for people
with dysarthria (n = 159) [18]. All six trials assessed in-
telligibility and almost all of the results were not statisti-
cally significant. The exception to this was for one of the
three types of perceptual ratings of speech recordings
made in the study by Halpern et al. [19] for which LSVT
gave the greater improvement (n = 14). Herd et al. [18]
concluded that the small number of participants exam-
ined, the low methodological quality of the trials evalu-
ated, and the possibility of publication bias resulted in
an inability to determine the superiority of any one type
of SLT over another. Since these reviews were published,
two further RCTs have been reported: the PD COMM
Pilot trial [13] (described below) and a trial comparing
LSVT LOUD® with LSVT ARTIC® (a second type of
LSVT focussing on increased movement amplitude di-
rected predominately to the orofacial-articulatory sys-
tem, but with the same dosing schedule and intensity)
with a no SLT intervention control in people with PD
and healthy controls [20]. The latter trial included 64
people with PD and measured sound pressure level
(SPL) differences and a modified Communications Ef-
fectiveness Index (CETI-M) at 1 and 7months. LSVT
LOUD® significantly increased SPL at 1 and 7months
compared to LSVT ARTIC® and control. Both LSVT
groups also showed a greater improvement than control
in CETI-M at 1 month, but this difference was not main-
tained at 7 months. A pilot trial (PD COMM Pilot) ran-
domised 89 people with speech problems into a three-
arm, assessor-blinded RCT to assess the feasibility and
to inform the trial design of a full-scale RCT [15]. Partic-
ipants were randomised to either LSVT LOUD®, stand-
ard NHS SLT or no intervention control in a 1:1:1 ratio.
The pilot trial showed a trend towards improvement in
the LSVT LOUD® and SLT groups over the control
group at 3 months, but the findings were not powered to
give a definitive answer.
The PD COMM trial design was informed by our PD
COMM Pilot trial, which was funded by The Dunhill
Medical Trust. The PD COMM trial is funded by the
UK National Institute for Health Research Health Tech-
nology Assessment programme (10/135/02). Further
support was provided by Professor Lori Ramig in the
form of free LSVT LOUD® training. The protocol is re-
ported using the Standard Protocol Items: Recommen-
dations for Interventional Trials (SPIRIT) [21] and
Template for Intervention Description and Replication
(TIDieR) [22] guidelines.
Methods/design
The PD COMM trial protocol can be found on: https://
www.birmingham.ac.uk/research/activity/mds/trials/
bctu/trials/pd/PD-COMM/investigators/documentation.
aspx (last accessed 10 September 2019). The trial re-
ceived ethical approval on 7 December 2015 by the West
Midlands NHS Research Ethics Committee (REC) (15/
WM/0443), with protocol version 4.0 (14 November
2018) currently in effect (see the ‘Protocol amendments’
section below for details). The project is sponsored by
the University of Birmingham (Research Governance
Team, University of Birmingham, Birmingham, B15
2TT).
PD COMM is a multicentre, phase III, three-arm, un-
blinded RCT where participants are randomised in a 1:1:
1 ratio to a no-intervention control group, NHS SLT or
LSVT LOUD®.
The primary objective of the trial is to evaluate the
clinical and cost-effectiveness of the two types of SLT
versus no SLT treatment (no SLT control) for people
with PD, but the trial will also compare the two types of
SLT (LSVT LOUD® versus standard NHS SLT). There-
fore, there will be three comparisons within the trial:
1. LSVT LOUD® versus no SLT control
2. Standard NHS SLT versus no SLT control
3. LSVT LOUD® versus standard NHS SLT
Patient-reported measures are being used to assess the
participant’s perception of how their voice impacts on
daily activities and their quality of life to assess clinical
effectiveness. The quality of life of carers will also be
assessed, and a cost-effectiveness analysis will be
performed.
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Participant characteristics
People will be eligible for recruitment into the trial if
they have idiopathic PD as defined by the 1988 UK PDS
Brain Bank Criteria [23]; they, or their carer, report
problems with speech or voice when asked and they
have no signs of dementia – typically this is determined
by the person with a PD clinician as per local practice.
Furthermore, they must not have evidence of laryngeal
pathology including: vocal nodules, a history of vocal
strain or previous laryngeal surgery as such patients may
not be suitable for LSVT LOUD®; and have not received
SLT for speech- or voice-related problems in the past 2
years, as there is some evidence that benefits of LSVT
may persist for 24 months [14].
Identification, recruitment and randomisation
The trial is designed to align with routine care, thus
minimising the burden for people with movement diffi-
culties. Participants will usually be identified during rou-
tine clinic appointments with their clinician or
Parkinson’s specialist nurse who will inform potentially
eligible patients of the trial and provide a copy of the
participant information sheet (PIS). The patient will be
given time to review the PIS and/or go through it with a
member of the team, typically the research nurse, and
will be given the opportunity to ask questions. Given the
low-risk nature of the trial, and the mobility limitations
of the population, participants may join the trial on the
same day that they discuss the trial and receive the PIS
or may come back at a later date if they prefer.
Following informed consent and completion of the
baseline assessment and questionnaires, the participant
can be randomised into the trial. Prior to randomisation,
the team will check the availability of speech and lan-
guage therapists at that site. Randomisation may be de-
ferred if the SLT intervention cannot be initiated within
the set time frames – however, the participant’s baseline
questionnaire needs to be completed within 2 weeks
prior to randomisation, so this should be factored in to
any planned delay of a patient’s randomisation. Typically
the research nurse, will obtain informed consent and
randomise the patient into the trial and liaise with the
speech and language therapist to ensure that SLT
(should they be randomised to therapy) starts within the
required time frame.
Following informed consent and completion of all
baseline data collection, participants will be randomised
at the level of the individual via a central secure web-
based randomisation system at the Birmingham Clinical
Trials Unit (BCTU) to ensure concealment of the next
treatment allocation. Typically, randomisation will be
performed by the research nurse. The randomisation
process will use a minimisation procedure with a
random element. The following minimisation variables
will be used:
 Age (≤ 59, 60–70, > 70 years)
 Disease severity measured using the Hoehn and
Yahr [24] staging (1.0–2.5, 3.0–5.0) and
 Severity of speech measured using the Voice
Handicap Index (VHI) [25] total score (≤ 33, mild
34–44, moderate 45–61, severe > 61)
Once randomised into the trial, NHS SLT should start
within 4 weeks and LSVT LOUD® should start within 7
weeks to enable the intervention to be completed prior
to the primary end point (at 3 months post randomisa-
tion). The trial will last for 77 months. Recruitment will
take place in approximately 42 sites around the UK (see
Table 1).
Interventions
Standard NHS SLT Standard NHS SLT is not prescrip-
tive and does not have standard content or dosage. It is,
therefore, not possible to predict the number of sessions
that will be provided. A survey of current UK SLT prac-
tice for PD [12] reported a median dose of six sessions
delivered over 42 days. The PD COMM Pilot trial found
the median dose to be six sessions (range 1–14) over an
average of 9.6 weeks (standard deviation 6.1 weeks) [13].
Treatment is typically tailored to the individual’s level
of difficulty or dysarthria severity and their interests as
individual need and clinical constraints. Treatment will
be individualised to suit each participant’s needs as per
local practice. It may include impairment-based inter-
ventions, compensatory interventions and augmentative
and alternative communication (ACC) strategies aimed
at improving communication and participation. The par-
ticipant’s family/carer(s) may be involved. Therefore, the
NHS SLT arm will encompass any SLT interventions
that are not LSVT LOUD® as per the LSVT LOUD®
protocol.
Treatments targeted at impairment level may include
exercises focussed on improving capacity, control and
co-ordination of respiration, techniques for improving
phonation intensity and co-ordination with respiration
(but not LSVT LOUD®), and exercises to improve the
range, strength and speed of the articulatory muscles
[16, 17]. Behavioural therapy may include interventions
aimed at reducing prosodic abnormality [26, 27] such as
exercises targeting pitch, intonation, stress patterns and
volume variation [16, 17, 26–28], and techniques to ad-
dress the overall rate of speech [16, 17] including the
use of therapeutic devices such as pacing boards [29,
30]. AAC strategies such as topic and alphabet supple-
mentation through communication books and boards
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may be employed [31] along with AAC devices such as
voice amplifiers, delayed auditory feedback systems and
masking devices [32–34]. The practice of pitch-limiting
voice treatment [35] may also be utilised within the
standard SLT intervention.
The above methods may include techniques used in
LSVT LOUD®, e.g. vocal intensity exercises, but will be
distinct by the individualised treatment, other SLT strat-
egies, lower intensity of delivery and (potentially) the use
of group intervention.
Dose will be determined by the therapist reflecting
participants’ individual needs, but the duration is un-
likely to exceed 12 weeks of treatment. Sessions will be
conducted by a suitably trained speech and language
therapist or therapy assistant on a one-to-one or group
basis per participant need and local practice. Sessions
may take place in out-patient clinics, the participant’s
home or in the community.
LSVT LOUD® The LSVT LOUD® intervention is pre-
scriptive and consists of four 50-min sessions per week
delivered over 4 weeks [36]. Each session follows a simi-
lar structure: 25 min of repeated and intensive
maximum-effort drills, and 25 min of high-effort speech
production tasks [36]. Participants will also be set 5 to
10min of home-based practice tasks on treatment days,
and up to 30min of home-based practice tasks on non-
treatment days [37].
Content will consist of repeated repetitions of sustained
‘ah’ phonation, maximum fundamental frequency-range
high- and low-pitch glides, and functional sentence repeti-
tion for the first half of each session, and exercises using
speech production hierarchy that progresses throughout
duration of the treatment programme (single word,
phrases, sentences, paragraph reading, conversation) dur-
ing the second half of the sessions [37]. Throughout all of
the sessions, the focus of the intervention will be to ‘think
loud’, maintaining the vocal loudness produced during
vowel phonation throughout all other tasks during the
treatment [36].
Sessions will be conducted by a suitably trained speech
and language therapist or therapy assistant on a one-to-
one basis. Sessions may take place in out-patient clinics,
the participant’s home or remotely using tele-LSVT
Table 1 Participating sites and principal investigators (PIs)
Trust PI
Aneurin Bevan University Health Board Alistair Church
Basildon and Thurrock University Hospitals NHS
Foundation Trust
Sigurlaud
Sveinbjornsdottir
Betsi Cadwaladr University Health Board Sam Abraham
Blackpool Teaching Hospitals NHS Foundation
Trust
David McGhee
Brighton and Sussex University Hospitals NHS Trust Romi Saha
Cardiff and Vale University Health Board Chris Thomas
Central London Community Healthcare NHS Trust Ayano Funaki
East Cheshire NHS Trust Monty Silverdale
Gloucestershire Hospitals NHS Foundation Trust Sangeeta Kulkarni
Great Western Hospitals NHS Foundation Trust Graham Lennox
Guy’s and St Thomas’ NHS Foundation Trust Thomasin Andrews
Harrogate and District NHS Foundation Trust Rosaria Buccoliero
Heart of England NHS Foundation Trust (now
University Hospitals Birmingham NHS Foundation
Trust)
Martha Pinkney
Homerton University Hospital NHS Foundation
Trust
Laetitia Sautin
Hywel Dda University Health Board Christopher James
Lancashire Teaching Hospitals NHS Trust Tahir Majeed
Leeds Teaching Hospitals NHS Trust Ioannis Mavroudis
London North West Healthcare NHS Trust Judy Anne Juada
NHS Ayrshire and Arran Andrew Watt
NHS Dumfries and Galloway Shona Donaldson
NHS Forth Valley Suvankar Pal
NHS Greater Glasgow and Clyde Steven Wishart
NHS Highland/Argyll and Bute Martin Wilson
NHS Lanarkshire Helen Morgan
NHS Lothian Gordon Duncan
NHS Tayside Derek Sutherland
Norfolk and Norwich University Hospitals NHS
Trust
Stephanie Cooper
Norfolk Community Health and Care NHS Trust Lauren Issacs
North Bristol NHS Trust Alan Whone
Northern Lincolnshire and Goole NHS Foundation
Trust
Shankar Kamath
Pennine Acute Hospitals NHS Trust Jason Raw
Powys Teaching UHB Jane Price
Royal Devon and Exeter NHS Foundation Trust Ray Sheridan
Sandwell and West Birmingham Hospitals NHS
Trust
Carl Clarke
St Helens and Knowsley Hospitals NHS Trust Dipen Gandecha
Taunton and Somerset NHS Foundation Trust Simon Cooper
The Walton Centre NHS Foundation Trust Malcolm Steiger
Torbay and South Devon NHS Foundation Trust Rachel Nashed
University Hospitals Bristol NHS Foundation Trust Theresa Allain
Table 1 Participating sites and principal investigators (PIs)
(Continued)
Trust PI
University Hospitals of South Manchester NHS
Foundation Trust (now Manchester University NHS
Foundation Trust)
David Ahearn
Bath and North East Somerset Community Health
and Care Services NHS
Veronica Lyell
Wye Valley NHS Trust Emma Wales
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software. Once the exercises have been established,
LSVT LOUD® may be delivered using the LSVT com-
panion software for a proportion of the time, in line with
local practice.
Control The control group will not receive any SLT for
their speech for 12 months, unless it becomes clinically
necessary. At the end of 12 months, participants will be
treated per local practice. If the participant needs SLT
prior to 12months, with their continued consent, they
will remain in the trial and be followed up as usual and
included in the trial analyses.
Participants are free to withdraw from the trial at any
time or they may agree to continue in the trial but not
comply with treatment. In the latter case they will con-
tinue to be followed up as per the protocol and the data
will be analysed according to the group that they were
randomised to (intention to treat).
Outcomes
Following the analysis of PD COMM Pilot, the design of
the trial was refined to reduce the burden on partici-
pants and speech and language therapists by excluding
the battery of vocal assessments and the Voice-related
Quality of Life [38] questionnaire.
Primary outcome
The primary outcome measure for the trial is patient re-
ported Voice Handicap Index (VHI) [25] total score at 3
months.
There was some discussion about the choice of pri-
mary outcome, as most previous trials had used vocal
loudness. The VHI was chosen given that it is patient-
reported, brief, (and from the pilot trial) well-completed
and, in our view, better reflects the focus of the trial.
Alongside the VHI, a battery of patient-reported out-
comes (PROs; see the ‘Secondary outcomes’ section) are
being collected, which cover a range of other important
areas. In the pilot trial, extensive vocal assessments were
carried out alongside the PROs. We decided not to
undertake vocal assessments within the PD COMM trial
as (1). the additional time involved was prohibitive; (2).
there was concern that since one of the trial interven-
tions (LSVT LOUD®) specifically focussed on vocal loud-
ness that the results might be skewed in favour of this
intervention and (3). the focus of the trial was on the
participants self-perception of functional communication
rather than vocal loudness.
Secondary outcomes
Patient reported: Subscales of the VHI [25]; Parkinson’s
Disease Questionnaire-39 (PDQ-39) [39]; Questionnaire
on Acquired Speech Disorders (QASD) [40]; EuroQol-
5D (5-level version) [41]; ICEpop Capabilities Measure
for Older Adults (ICECAP-O) [42]; resource utilisation;
and adverse events (AEs).
Carer reported: Carer quality of life (Parkinson’s Dis-
ease Questionnaire–Carers) [43].
Other data collected includes
Demographics including height (baseline only), weight
and Hoehn and Yahr stage (at baseline and 12months)
[24]; PD medication; Abbreviated Mental Test [44]
(intervention arms only), therapy logs including home-
based therapy diaries, NHS therapy notes and a global
rating scale (Transition item).
Adverse events
A risk assessment of the PD COMM trial has been per-
formed with the SLT interventions considered to be of
low risk. From the literature, the only reported AE asso-
ciated with the interventions was a small increased risk
of vocal strain or abuse; however, none were reported in
the PD COMM Pilot trial. This risk will be minimised:
speech and language therapists are trained to identify
and rehabilitate vocal strain so, if present, the therapist
will be able to identify and address it. No other risks are
expected to arise from taking part in the trial. It is,
therefore, reasonable to collect only targeted AEs.
For participants in either therapy arm, any vocal strain
or abuse believed to be associated with treatment will be
identified by the therapists at the participants’ therapy
session and will be reported in the AE log.
In all trial arms, BCTU will also check the participant-
reported resource usage form to ensure that no vocal
strain or abuse has occurred following participants
reporting out-patients appointments with ear, nose and
throat (ENT) specialists. At the 12-month clinical visit,
the medical professional will also check whether any
AEs have occurred since entering the trial.
Serious adverse events (SAEs) are events that cause
death, are life-threatening, require or extend an existing
hospitalisation, result in persistent or significant disabil-
ity or incapacity; or, are otherwise considered medically
significant by the investigator. SAEs that are not related
to vocal strain or abuse are excluded from expedited no-
tification during the course of the trial and will be col-
lected in the resource usage and 12-month clinical case
report form (CRF).
Data collection
Data is collected in clinic at baseline and 12months post
randomisation at usual clinic appointments, and patient-
reported outcome data is also collected at 3, 6 and 12
months post randomisation by postal questionnaires to
the participant which are returned directly to BCTU.
Participants who do not comply with their treatment al-
location will be followed up as other participants unless
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they chose to withdraw from the trial. Data is reviewed
on receipt, and return rates and completeness are closely
monitored throughout the trial to ensure patient reten-
tion. The Trial Management Group review return and
completeness rates and can determine whether to trigger
further review or monitoring.
Figure 1 provides a flowchart of the trial design and
Table 2 denotes the schedule of events. Data is sent
to BCTU where they are securely held in restricted-
access areas and entered onto a bespoke trial data-
base. For participants randomised to the intervention
arms, further data around the interventions including
therapy logs and therapy notes is sent to BCTU (see
below). Redacted therapy notes and anonymised data
sets will be sent to researchers at Glasgow Caledonian
University for the intervention description analysis.
This data will be integrated with the process evalu-
ation data collected and held at the University of
Bangor.
Treatment dose and fidelity
The speech and language therapists will complete an ini-
tial interview log including the Abbreviated Mental Test
and intervention record forms at each treatment session
for participants receiving SLT. Furthermore, in the
LSVT LOUD® arm and where prescribed in the NHS
SLT arm, participants will complete home-based therapy
diaries. Therapists will also complete standard NHS
therapy notes; upon trial treatment completion, a
pseudo-anonymised (i.e. participant is only identified by
trial number) version of these will be sent to the re-
search team.
Process evaluation
In order to evaluate the implementation of PD COMM
interventions, a process evaluation will be carried out
alongside PD COMM. The process evaluation team led
by Bangor University will employ a number of ap-
proaches to data collection, including:
 Qualitative interviews with PD COMM participants
 Qualitative interviews with PD COMM therapists
 Critical incident reports
 Therapist’s questionnaire
A detailed protocol for these analyses including inter-
vention description has been published [45].
The analysis of process evaluation data will focus on
the practical implementation of the trial interventions,
including how these were tailored to individual patient
and other circumstances.
Sample size
The primary outcome is the mean difference in the VHI
total score at 3 months across the three comparisons:
LSVT LOUD® versus control; standard NHS SLT versus
control; and LSVT LOUD® versus standard NHS SLT.
Data from the PD COMM Pilot trial was used to inform
the sample size calculations for this trial as the minimal
clinically important difference (MCID) for the VHI has
not been established in PD patients. In the PD COMM
Pilot trial, a difference of around 10 points in VHI total
score was observed at 3 months between SLT and con-
trol for both types of SLT (standard NHS and LSVT
LOUD®) versus control comparisons. To detect a 10-
point difference in VHI total score between arms at 3
months (using a two-sided t test and the upper standard
deviation of 26.27 obtained from the VHI baseline data
from the pilot trial; effect size 0.38), with 80% power and
α = 0.01, we need 163 participants per arm. Allowing for
10% drop-out will require 182 participants per arm, so
546 participants in total.
Patients who have Parkinson’s and problems with their speech 
or voice are identified by physician, nurse or therapist
Physician, nurse or therapist discusses trial and provides 
potential participant with Patient Information Sheet
Physician, nurse or therapist confirm eligibility, answer any 
outstanding questions and take consent
Following consent, baseline assessments are performed, and 
then the participant is randomised in to the trial
LSVT No SLT (Control)
3, 6 and 12 month follow-up assessments
Complete trial
Standard NHS 
SLT
Fig. 1 Flow diagram of trial design
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Statistical analysis
All primary analyses (for both the primary and second-
ary outcomes) will be by intention to treat. Participants
will be analysed in the treatment group to which they
were randomised, and all participants will be included
whether or not they received the allocated treatment.
This is to avoid any potential bias in the analysis. For all
tests, summary statistics (e.g. mean differences) will be
reported along with 95% confidence intervals and p
values from two-sided tests. A p value of < 0.01 will be
considered statistically significant, as per the sample size
calculations to take into account the multiple treatment
comparisons being undertaken.
There will be no interim analyses.
The analysis and interpretation of qualitative data, and
its integration with quantitative data on intervention
provision, will be performed between researchers at Ban-
gor University (Professor Christopher Burton) and Glas-
gow Caledonian University (Professor Marian Brady),
with input from University College London (Dr Chris-
tina Smith) and King’s College London (Professor Cath-
erine Sackley).
Primary outcome analysis
The primary outcome measure is the VHI total score at
3 months. A linear regression model will be used to esti-
mate differences in the VHI total score at 3 months be-
tween the two arms of interest, with the VHI baseline
score and the minimisation variables age and severity of
PD (Hoehn and Yahr) included in the model as
covariates.
Secondary outcome analyses
The majority of the secondary outcome measures (e.g.
PDQ-39) are continuous measurements and will be ana-
lysed in a similar way to that described for the primary
analysis: a linear regression analysis adjusting for rele-
vant baseline score and all of the minimisation variables
(baseline VHI, age and severity of PD). As per the pri-
mary outcome, the primary analysis for the secondary
outcomes will be based on the 3-month data.
To assess whether any treatment effect is maintained,
participant- and carer-completed questionnaires are also
being collected at 6 and 12 months post randomisation.
Data collected at 6 and 12 months will be analysed using
the same methods as described above. Further analysis
using a repeated measures model will also be performed
using all data over the 3-, 6- and 12-month assessment
points.
A global rating scale (Transition item) will be com-
pleted by the participant and carer separately at the 3-
month time point. This data will be used to calculate an
MCID for the VHI in this population.
Adverse events and safety data will be summarised de-
scriptively by treatment arm, and the number of events
and percentage of participants experiencing any AE
Table 2 Time and event schedule
Measure Enrolment Assessment time
Allocation t = 0 3 months 6 months 12 months
Enrolment
Informed consent ✓
Eligibility ✓
Allocation ✓
Interventions
Initial interview log and treatment record form (all sessions) ✓a
Home-based therapy diary ✓b
Assessments
Baseline case report form ✓
VHI; PDQ-39; QASD; EQ-5D-5 L; ICECAP-O ✓ ✓ ✓ ✓
Resource Usage Questionnaire ✓ ✓ ✓
Global rating score (Transition item) ✓
PDQ-Carer ✓ ✓ ✓ ✓
Adverse event log ✓c
12-month case report form ✓
aFollowing each therapy session for participants in the two SLT treatment arms only
bCompleted at home by the participant as recommended in their SLT therapy session
cOnly required for participants randomised to a treatment arm
Key: EQ-5D EuroQol 5-dimension, 5-level questionnaire, ICECAP-O ICEpop Capabilities Measure for Older Adults, QASD Questionnaire on Acquired Speech
Disorders, PDQ-39 Parkinson’s Disease Questionnaire-39, SLT Speech and Language Therapy, VHI Voice Handicap Index
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reported. It is not expected that there will be many AEs
as a result of the intervention, but the number of partici-
pants reporting an AE will be compared using a chi-
squared test, with relative risks and 95% confidence in-
tervals reported (if appropriate).
Planned subgroup analyses
Subgroup analyses will be performed for the primary
outcome to assess whether there are differences in treat-
ment effect by the minimisation variables: age; baseline
voice severity (as measured by VHI); and PD severity (as
measured by Hoehn and Yahr). The trial is not powered
to detect differences in treatment effect in these sub-
groups and, therefore, these analyses will be treated as
purely hypothesis generating.
Health economics analysis
The economic evaluation will estimate the cost-
effectiveness of LSVT LOUD® or standard NHS SLT
compared to no SLT treatment (control) in PD. The
base-case economic evaluation will be undertaken from
the UK NHS and personal social services (PSS) perspec-
tive, with further analysis from a broader societal per-
spective, over 12 months’ follow-up.
A cost-effectiveness analysis will use the primary out-
come (VHI) to calculate the cost per unit improvement
in VHI score, and a cost-utility analysis will use re-
sponses from the EQ-5D-5 L to calculate cost per
quality-adjusted life year (QALY) gained. Resource-use
data will be collected on PD-related medication, primary
care and secondary care healthcare utilisation, including
the use of therapy services, and use of social services in-
cluding formal care. Further information will be col-
lected on time off work, participant out-of-pocket costs
and costs incurred by informal carers, in order to inform
analysis from a societal perspective. The cost of deliver-
ing the LSVT LOUD® intervention and NHS SLT, in-
cluding length and number of sessions and any training
required will be determined within the trial. Data will be
collected using a participant-completed resource utilisa-
tion questionnaire (at 3, 6 and 12months) and the
therapist-completed initial interview logs and treatment
record forms. Unit costs from routine sources will be ap-
plied to resource-use data [46, 47]. Health-related quality
of life will be assessed using the EQ-5D-5 L [41] col-
lected at baseline, 3, 6 and 12months. The crosswalk
value set will be applied to patient responses to obtain
utility scores, in line with current NICE recommenda-
tions and QALYs calculated using the ‘area under the
curve’ approach. The ICECAP-O [42] will also be used
to capture changes in participants’ capabilities, allowing
a broader assessment of benefits to patients.
Incremental cost-effectiveness and cost-utility analyses
will be undertaken to estimate the incremental cost per
unit of outcome gained, adjusting for baseline covariates.
Two sets of comparisons will be undertaken. In line with
convention, strategies will be ordered from least to
greatest cost, with each strategy compared against the
next more costly strategy, and strategies which are domi-
nated or extendedly dominated subsequently excluded.
A separate analysis will also consider the three pair-wise
comparisons as specified in the statistical analysis. Both
deterministic and probability sensitivity analysis will be
undertaken and cost-effectiveness acceptability curves
will be produced to reflect the probability the interven-
tion will be cost-effective at different willingness to pay
thresholds, in terms of cost per unit of outcome gained.
Dissemination
The trial results will be disseminated widely through sci-
entific conferences and peer-reviewed publications. Col-
laborators will be informed of the trial results at a
national trial results meeting and participants will be
sent a newsletter thanking them for their support and
informing them of the trial results. We will also use so-
cial media and work with the Universities media ser-
vices, National Institute of Health Research (NIHR)
Health Technology Assessment (NIHR HTA) dissemin-
ation services and the Parkinson’s UK charity to broaden
our dissemination to key stake-holders and the wider
community.
Roles and responsibilities
The study design, collection, management, analysis and
interpretation of the data, publishing the data is the re-
sponsibility of the chief investigator, and the Collabora-
tive Group, the trial is managed by the BCTU, with
additional support for Scottish sites being provided by
Glasgow Caledonian University. The process evaluation
is managed by the University of Bangor and the inter-
vention description analysis is managed by Glasgow
Caledonian University. The sponsor and funder do not
have a role in the above activities.
Oversight of the trial is performed by the Trial Man-
agement Group, an independent Data Monitoring Com-
mittee (DMC) and Trial Steering Committee (TSC). The
DMC and TSC membership (see Table 3) was agreed
with the funder; these committees meet at least annually
to review the data and progress of the trial. Annual re-
ports are submitted to the NHS REC and monthly up-
dates against pre-determined milestones are sent to the
funder.
Discussion
The PD COMM trial is already the largest trial of SLT
in PD to date (as of 10 September 2019, 329 participants
have been recruited). It will provide robust evidence as
to the effectiveness and cost-effectiveness of two types of
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SLT for people with PD enabling them, their clinicians
and NHS decisions-makers to make informed choices.
There will also be benefits beyond the immediate trial
results: the group has developed a research network of
speech and language therapists in 42 sites around the
UK, participated, and provided training in, LSVT LOUD®
(courtesy of Dr Lori Ramig), trials, other aspects of PD
and research into SLT and information on best practice.
This project will lay the foundation for further trials in
SLT and lower the barriers to future research. Further-
more, we will develop a clear understanding of the range
of SLT practice around the UK for people with speech
or voice problems as a consequence of PD, in terms of
dosage, content and availability.
Trial status
Protocol version number and date: version 4.0 (14 No-
vember 2018).
The first participant was recruited into the trial on 11
October 2016. Recruitment is ongoing with an expected
recruitment end date of 30 November 2020.
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